retatrutide phase 2 type 2 diabetes weight loss 2024 trial 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: Retatrutide: A Promising Option for

Hall EM, Acevedo J, Lpez FG, Corts S, Ferreccio C, Smith AH, Steinmaus CM

Bottom Line The Path to $1 Trillion Current State (Nov 2025): Stock Price: ~$990 Market Cap: ~$885-930B Distance to $1T: ~7-13% away Catalysts Ahead: Orforglipron approval (March 2026 expected) Continued GLP-1 market expansion Kisunla (Alzheimer's) adoption ramp Pipeline readouts in oncology and immunology For Long-Term Investors: Volatility is part of the journey

Bottom line: MeAgain is built for where GLP-1 tracking is going tracking, context, and support in one focused daily companion

Unlock Place the pen firmly on the skin and turn the lock ring to unlock

Peptide Therapy and traditional treatment methods each serve unique purposes and offer different benefits

They have the strongest evidence bases, the most practical benefits, and the best cost-to-benefit ratios